These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30041014)

  • 21. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abbreviated New Drug Applications and 505(b)(2) Applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Oct; 81(194):69580-658. PubMed ID: 27731961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues.
    Huang SM; Lesko LJ; Williams RL
    J Clin Pharmacol; 1999 Oct; 39(10):1006-14. PubMed ID: 10516934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA review divisions: performance levels and the impact on drug sponsors.
    Milne CP; Kaitin KI
    Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New indications for already-approved drugs: time trends for the new drug application review phase.
    Spivey RN; Lasagna L; Trimble AG
    Clin Pharmacol Ther; 1987 Apr; 41(4):368-70. PubMed ID: 3829575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of quality review issues and the association with application characteristics for new drug applications in first-cycle reviews.
    Liou JS; Chang LC
    Regul Toxicol Pharmacol; 2019 Nov; 108():104448. PubMed ID: 31446093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the approved Risk Evaluation and Mitigation Strategy programs for New Drug Applications and Biologics Licensing Applications.
    Johnson NA; Priefer R
    Regul Toxicol Pharmacol; 2019 Feb; 101():53-56. PubMed ID: 30473489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From idea to market: the drug approval process.
    Lipsky MS; Sharp LK
    J Am Board Fam Pract; 2001; 14(5):362-7. PubMed ID: 11572541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approval of modified-release products by FDA without clinical efficacy/safety studies: A retrospective survey from 2008 to 2017.
    Wang YL; Chang YT; Yang SY; Chang YW; Kuan MH; Tu CL; Hong HC; Lai IC; Gau CS; Hsu LF
    Regul Toxicol Pharmacol; 2019 Apr; 103():174-180. PubMed ID: 30711621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of Patient-Reported Outcome Labeling in the United States (2011-2015).
    Gnanasakthy A; Mordin M; Evans E; Doward L; DeMuro C
    Value Health; 2017 Mar; 20(3):420-429. PubMed ID: 28292487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory Considerations in the Development of Radiation-Drug Combinations.
    Walker AJ
    Int J Radiat Oncol Biol Phys; 2021 Dec; 111(5):1140-1144. PubMed ID: 34348173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of recently approved 505(b)(2) new drug applications (2010-2012): role of clinical pharmacology.
    Agarwal S; Qiu W; Sahajwalla C
    J Clin Pharmacol; 2014 Dec; 54(12):1330-6. PubMed ID: 24958449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA review practices and priorities for drugs used in cancer treatment.
    Kobayashi K; DeLap RJ
    Ann N Y Acad Sci; 2001 Dec; 949():341-4. PubMed ID: 11795373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration.
    Bai JPF; Earp JC; Florian J; Madabushi R; Strauss DG; Wang Y; Zhu H
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1479-1484. PubMed ID: 34734497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.